首页> Chinese medicine> Atractylenolide I ameliorated the growth and enzalutamide resistance of castration-resistant prostate cancer by targeting KIF15.

Atractylenolide I ameliorated the growth and enzalutamide resistance of castration-resistant prostate cancer by targeting KIF15.

导出 OA

翻译打印收藏纠错

第一作者： Chenglin,Han

第一单位： Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.

作者： Chenglin,Han ^[1] ; Bin,Yang ^[1] ; Yuxuan,Deng ^[1] ; Peng,Hu ^[1] ; Bintao,Hu ^[1] ; Xiaming,Liu ^[1] ; Tao,Wang ^[1] ; Chengbao,Li ^[2] ; Jihong,Liu ^[3] ; Huixing,Yuan ^[4]

作者单位： Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China. ^[1] Department of Anesthesiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. ^[2] Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China. jhliu@tjh.tjmu.edu.cn. ^[3] Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China. hobby8097@sina.com. ^[4]

关键词 AR/AR-V7 ATR-I CRPC KIF15 Ubiquitin-proteasomal degradation

DOI 10.1186/s13020-025-01086-1

PMID 40087774

发布时间 2025-03-18

基金项目

82072838/National Natural Science Foundation of China ZR2021QH217/Shandong Provincial Natural Science Foundation 2021ghry008/Start-up Funds for Returnees from Tongji Hospital

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交